Review Article
Cancer Vaccines Designed Based the Nanoparticle and Tumor Cells for the Treatment of Tumors: A Perspective
Table 1
Some pivotal trials for tumor vaccines.
| Vaccine platform type | Product/compound name | Antigen(s) | Identifier (phase, name) | Findings | References |
| Tumor cell-based | Belagenpumatucel-L (Lucanix™) | / | NCT00676507 (phase 3) | Second interim analysis, futility | [59] |
| Tumor cell-based | Canvaxin™ (CancerVax) | / | NCT00052130 (phase 3, MMAIT-III) | Study was terminated (low probability) | [60, 61] |
| DC-based | Peptide-loaded DC vaccine | Several MHC restricted peptides | (phase 3) | Study was prematurely closed | [62] |
| Protein | BEC2 | GD3 | NCT00037713 (phase 3, SILVA) | Population heterogeneity and study design | [63] |
| Protein | THERATOPE® | STn | NCT00003638 (phase 3) | Tumor burden; treatment duration | [64] |
|
|